A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Inclusion criteria

* Each subject must satisfy all of the following criteria to be enrolled in the study: * Subject must understand and voluntarily sign an Informed Consent Form prior to any study-related assessments/procedures being conducted. * Subject is able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules and other protocol requirements. * Subject is ≥ 18 and ≤ 80 years of age at the time of signing the informed consent. * Subject has a body mass index between 18 and 40 kg/m2 (inclusive). * Subject is afebrile * Subject has a normal or clinically acceptable 12-lead Electrocardiogram at screening. In addition: * If male, subject has a QTcF value ≤ 470 msec at screening. * If female, subject has a QTcF value ≤ 480 msec at screening. * Subject agrees to comply and abide by the requirements and restrictions outlined in the CC-122 Pregnancy Prevention Plan for Subjects in Clinical Trials. * Female subjects must have been surgically sterilized (hysterectomy, bilateral oophorectomy, proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone level of\> 40 IU/L at screening). * Male subject must practice true abstinence\* (which must be reviewed on a monthly basis, as applicable) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions (if applicable) and for at least 90 days following study drug discontinuation, even if he has undergone a successful vasectomy. * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Period abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Inclusion Criteria for Subjects with Mild, Moderate, or Severe Renal Impairment. * Each subject with mild, moderate, or severe renal impairment must also meet ALL of the criteria listed below for entry: * Subject has mild, moderate, or severe (not requiring dialysis) renal impairment as defined by Estimated glomerular filtration rate (eGFR) at screening. * Subject has supine systolic BP: 90 to 180 mmHg, supine diastolic BP: 60 to 110 mmHg, and pulse rate: 40 to 110 bpm. * Must be medically stable for at least 1 month before study drug administration with clinically acceptable medical history, Physical exam (PE), clinical laboratory tests, vital signs, and 12-lead ECGs consistent with the underlying stable mild moderate or severe renal impairment condition, as judged by the Investigator. * Must be stable in concomitant medication regimen (defined as not starting a new medication\[s\] or a change in the dosage or frequency of the concomitant medication\[s\] within 7 days or 5 half-lives \[whichever is longer\] before dosing with study drug). Inclusion Criteria for a Matched Healthy Subject * Each matched healthy subject must meet ALL the criteria listed below for entry: * Subject has supine systolic BP: 90 to 160 mmHg, supine diastolic BP: 50 to 100 mmHg, and pulse rate: 40 to 100 bpm * Must be free of any clinically significant disease that would interfere with the study evaluations. * Must have normal renal function, as defined by an eGFR ≥ 90 mL/min/1.73 m2 (calculated using the Modification of Diet in Renal Disease (MDRD) equation). * Must match subjects in Group 1, 3, and 5 with respect to sex, age (± 15 years), and weight (± 20%). * Must be in good health as determined by past medical history, PE, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (i.e., hematology, chemistry, and urinalysis) and 12-lead ECGs must be within normal limits or clinically acceptable as judged by the Investigator.